Clitoral and vaginal engorgement during sexual stimulation depend in part on the increase of arterial in¯ow. It has been shown that apomorphine (APO), a non-selective dopamine receptor agonist, produces penile erection by activating dopaminergic receptors in the central nervous system. Our aim was to study whether systemic administration of APO improves the hemodynamic mechanism of clitoral and vaginal engorgement in the rabbit.
Introduction
Apomorphine (APO), a central non-selective dopamine receptor agonist with sedative and antiparkinsonian properties, has a well-documented erecto-genic effect in the penis. 1 ± 6 Systemic administration of APO has been shown to induce penile erection in about 60% of healthy men. 1 ± 3 Systemic APO has also been effective in improving penile erection in patients with idiopathic or psychogenic erectile dysfunction. 4 ± 6 The erectogenic effect of APO appears to involve activation of dopaminergic receptors in the central nervous system; 7 however the precise mechanism remains unclear. A recent study in the rat showed that APO-induced penile erection may involve changes in erectile tissue vascular resistance. 8 Our previous studies with the female rabbit model have shown that nerve stimulation-induced clitoral and vaginal engorgement depends on the increase of intracavernosal and vaginal blood¯ows. 9 It is believed that electrical stimulation of the parasympathetic pelvic nerve may lead to relaxation of clitoral cavernosal and vaginal wall tissues, thereby allowing for increase of clitoral intracavernosal and vaginal wall arterial in¯ow. 9 Relaxation of clitoral cavernosal smooth muscle appears to be mediated by nitric oxide (NO) while the regulatory mechanism of vaginal tissue relaxation remains controversial. 10 Central control of clitoral cavernosal smooth muscle contractility and vaginal wall tone has not been thoroughly investigated.
APO has been shown to facilitate sexual receptivity and induce mating behavior in female rats. 11, 12 However the role of APO on the hemodynamic mechanism of clitoral and vaginal engorgement has not been previously investigated. The aim of our present study was to determine whether systemic administration of APO enhances clitoral intracavernosal and vaginal wall blood¯ow during nerve stimulation-induced sexual arousal and improve the quality of clitoral and vaginal engorgement in the rabbit.
Methods
The New Zealand white female rabbits (n 6, 3.5 ± 4 kg) were anesthetized with intramuscular injection of ketamine (35 mgakg) and xylazine (5 mgakg). Anesthesia was maintained with 0.2 ml intravenous bolus injections of pentobarbital (25 mgaml) as needed. A 20 gauge angiocatheter was placed into the right carotid artery and connected to a transducer for measurement of systemic arterial pressure. A midline abdominal incision was made and the vaginalaclitoral branch of the pelvic nerve was dissected. Nerve stimulation (10 V, 8 ms, 16 Hz for 30 s) was performed with a Harvard subminiature electrode placed around the vaginalaclitoral branch of the pelvic nerve and connected to a Grass SD-9 stimulator.
Clitoral intracavernosal and vaginal wall blood ows were measured with a laser Doppler¯ow probe placed directly into the clitoral cavernosal tissue or into the vaginal wall and connected to a laser Doppler¯owmeter (Transonic Systems, Inc., Ithaca, NY). Clitoral intracavernosal and vaginal wall pressures were measured by angiocatheters inserted to the organs and connected to transducers. Calibration of pressure measurement was accomplished utilizing an external aneroid sphygmomanometer introduced into the system.
Apomorphine hydrochloride powder, a gift from Pentech Pharmaceutical Inc., was dissolved in dimethylsulfoxide (DMSO) and then diluted in distilled water. At the time of the study, arterial blood pressure and clitoral intracavernosal and vaginal wall blood¯ows and pressures were recorded before and then after stimulation of the vaginalaclitoral branch of the pelvic nerve. After this, APO was administered through the ear vein in a dose ± response manner (0.05, 0.1, 0.2, 0.3 and 0.4 mgakg). The time interval between injections of APO was 30 min. The effect of APO administration on arterial blood pressure and nerve stimulationinduced increase of clitoral intracavernosal and vaginal wall blood¯ows and pressures was recorded.
Data recording and statistical analysis
An eight-channel heat writing physiologic recorder (Astromed, Inc., West Warwick, RI) was utilized to obtain permanent recording of systemic blood pressure and clitoral intracavernosal and vaginal wall blood¯ows and pressures. Data is expressed as mean AE standard error of the mean. Student's ttest was utilized for statistical analysis. Statistical signi®cance was determined at the P`0.05 level.
Results

Effect of APO on clitoral intracavernosal blood¯ow
Stimulation of the vaginalaclitoral branch of the pelvic nerve caused a signi®cant increase in clitoral intracavernosal blood¯ow before APO administration ( Figure 1 ). Intravenous administration of APO (0.05 ± 0.2 mgakg) did not affect baseline clitoral intracavernosal blood¯ow while causing a concentration dependent increase in nerve stimulationinduced peak clitoral intracavernosal blood¯ow (n 6, Figure 1 ). Intravenous APO at concentration of 0.1 and 0.2 mgakg caused a statistically signi®cant increase in nerve stimulation-induced peak clitoral intracavernosal blood¯ow compared to that Figure 1 Effect of i.v. administration of APO on nerve-stimulated peak clitoral intracavernosal blood¯ow (n 6). *Statistically signi®cant increase in peak clitoral intracavernosal blood ow after nerve stimulation compared with before stimulation.
Statistically signi®cant increase in nerve-stimulated peak clitoral intracavernosal blood¯ow after APO administration compared with before APO administration (0 mgakg). 
Effect of APO on vaginal wall blood¯ow
Stimulation of the vaginalaclitoral branch of the pelvic nerve signi®cantly increased vaginal wall blood¯ow before APO administration ( Figure 2 ). Intravenous administration of APO did not produce a signi®cant effect on basal vaginal wall blood¯ow while increasing nerve stimulation-induced peak vaginal wall blood¯ow compared to that observed before APO administration (n 6, Figure 2 ). This effect of APO on vaginal wall blood¯ow was statistically signi®cant at 0.1 and 0.2 mgakg ( Figure  2 ). Intravenous APO at concentration of 0.3 mgakg was less effective in increasing nerve stimulationinduced peak vaginal wall blood¯ow compared with 0.2 mgakg. Intravenous APO at concentration of 0.4 mgakg produced adverse effect on nerve stimulation-induced peak vaginal wall blood¯ow ( Figure  2 ).
Effect of APO on clitoral intracavernosal and vaginal wall pressure
Intravenous administration of APO tended to increase nerve stimulated peak clitoral intracavernosal and vaginal wall pressures but this effect was not statistically signi®cant (n 3, Figures 3 and 4) .
Effect of APO on systemic arterial pressure
Intravenous administration of APO caused a concentration dependent decrease in diastolic arterial pressure while having minimal effect on systolic arterial pressure ( Figure 5 ). 
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Discussion
During female sexual arousal clitoral and vaginal engorgement develop. Physiologically, clitoral and vaginal engorgement depend in part on the decrease of vascular resistance and concomitant increase of clitoral intracavernosal and vaginal blood¯ows. 9 In our previous studies with the rabbit, we showed that electrical stimulation of the vaginalaclitoral branch of the pelvic nerve caused signi®cant increase in intracavernosal and vaginal wall blood¯ows leading to clitoral and vaginal engorgement. 9 Likewise, Doppler ultrasonography in humans has shown that vaginal pressure stimulation causes up to an 11-fold increase in clitoral intracavernosal blood¯ow leading to clitoral engorgement. 14 It is believed that increase of clitoral intracavernosal and vaginal wall blood¯ow results in part from a decrease of vascular resistance and relaxation of clitoral cavernosal and vaginal wall tissues. Our recent studies have shown that relaxation of rabbit clitoral cavernosal smooth muscle is mediated by NO. 10 Burnett et al have demonstrated immunohistochemically NO synthase (NOS) subtypes expression in human clitoral cavernosal tissue supporting the involvement of NO in the regulation of clitoral smooth muscle contractility and the development of clitoral engorgement. 15 We also found in the rabbit that vaginal smooth muscle relaxes following exposure to NO donors and also to vasoactive intestinal polypeptide (VIP). 10 However, the precise neuroregulatory mechanism of vaginal smooth muscle relaxation remains to be characterized. While local neurotransmitters in the clitoral corporal cavernosa and vaginal wall have been investigated to some extent, the central mechanism of clitoral and vaginal engorgement remains unknown.
Our present studies in the rabbit showed that systemic administration of APO did not affect basal clitoral intracavernosal and vaginal wall blood¯ow while causing a signi®cant increase in nervestimulated peak blood¯ows in these organs. The precise mechanisms by which APO enhances stimulated and not basal clitoral intracavernosal and vaginal blood¯ows remain unknown. APO at concentrations of 0.1 and 0.2 mgakg was most effective in increasing nerve-stimulated peak clitoral intracavernosal and vaginal wall blood¯ows. This may suggest the involvement of dopaminergic receptors in regulating the hemodynamic mechanism of clitoral and vaginal engorgement. Systemic APO tended to increase nerve-stimulated peak intracavernosal and vaginal wall pressures, but failed to produce a statistically signi®cant effect. One explanation may be that APO may enhance arterial in¯ow to the clitoral intracavernosal spaces and vaginal wall but does not interfere with out¯ow resistance in these organs.
The precise mechanism of APO-induced increase of clitoral intracavernosal and vaginal wall blood ow is not known. Since the clitoris is the embryological homolog of the penis there are physiological similarities between clitoral cavernosal and penile cavernosal tissues function. 10 APO-induced enhancement of penile erection and APO-induced improvement of clitoral engorgement may involve similar central and local neurological mechanisms. Studies in the male rat have shown that systemic administration of APO produces a`penile erectiona stretching yawning syndrome'. This APO-induced penile erection and yawning was shown to be inhibited by central dopamine receptor antagonists such as sulpiride, 16 haloperidol 17 and metoclopramide, 18 but not by peripheral dopamine receptor antagonists such as domperidone which cannot pass the blood ± brain barrier. 19, 20 These ®ndings would suggest that APO-induced penile erection is mediated by central mechanisms that involves activation of dopamine receptors. One site of central action of APO is believed to be the paraventricular nucleus of the hypothalamus, since APO-induced penile erection is abolished in the presence of paraventricular nucleus lesions 21 while direct administration of APO into the paraventricular nucleus causes penile erection. 22 Melis et al have shown that APO increases NO production in the paraventrucular nucleus of hypothalamus which mainly occurs through activation of D2 but not D1 receptors. 23 They have also shown that APO-induced penile erection, yawning and increase in central production of NO can be inhibited by NOS inhibitors administered systemically or centrally. 23 These ®ndings have suggested that NO production in the paraventricular nucleus of the hypothalamus may play a role in APO-induced penile erection. Another peptide, which was proposed to be involved in APO-induced penile erec- Systemic administration of apomorphine T Tarcan et al tion, is oxytocin since oxytocin antagonists have been shown to inhibit APO-induced penile erection. 24 Paick and Lee have suggested that APO-induced penile erection may involve the same central neural mechanism as the physiological erection. 8 It has been shown that the erectogenic effect of systemically administered APO requires intact cavernosal nerve and normal serum level of testosterone. 25 ± 27 Melis et al and Heaton et al have shown that APOinduced penile erection and yawning were abolished in castrated rats, but restored after exogenous testosterone treatment. 25, 26 In castrated rats, other sex hormones such as estradiol, progesterone or 5-dihydrotestosterone failed to restore APO-induced penile erection. 25 These observations would suggest that the erectogenic effect of APO may be in part mediated by the neurotransmitters involved in cavernosal smooth muscle relaxation and by sex hormones.
Concentration-dependent effects of APO on clitoral intracavernosal and vaginal wall blood¯ows are consistent with those reported in penile erection. For example, Sharifzadeh et al have found that subcutaneous injection of low dose APO (0.05 ± 0.5 mgakg) induces penile erection whereas higher doses produce adverse effect. 28 Zarrindast et al have investigated the dose-dependent erectogenic effect of APO in relation to receptor subtypes. 29 The authors found that the inhibitory effect of high doses of APO was abolished in the presence of a D1 antagonist. It was concluded that the erectogenic effect of low doses of APO involves D2 receptors, whereas the inhibitory effect of high dose of APO may be mediated by D1 receptors. The hypothesis that D2 receptor activation plays a leading role in APO-induced penile erection is also supported by studies of Melis et al who have shown that APOinduced increased central NO involves D2 but not D1 receptors. 25 In contrast to these studies, other investigators have reported that the erectogenic effect of APO occurs through activation of both D1 and D2 receptors. 7 For example, Melis et al have shown that APO-induced penile erection in rats can be inhibited by haloperidol (non-selective dopamine receptor antagonist) or sulpiride (a selective D2 antagonist) and also by SCH 23390 (a selective D1 antagonist). 23 Likewise, Dehpour et al have shown that both sulpiride and haloperidol inhibit APOinduced penile erection in rats whereas the combination of two drugs showed a greater inhibitory effect. 30 Therefore, the involvement of different types of dopamine receptors in APO-induced penile erection and female sexual arousal function remains controversial and require further investigation.
Conclusion
Our studies show that systemic administration of APO produces a concentration-dependent increase in clitoral intracavernosal and vaginal wall blood ows during nerve stimulation-induced clitoral and vaginal engorgement in the rabbit. A concentration of 0.2 mgakg appears to be the most effective dose in increasing peak clitoral intracavernosal and vaginal wall blood¯ows. Systemic administration of APO at concentrations greater than 0.2 mgakg was less effective or produced adverse effects on nerve stimulation-induced peak clitoral intracavernosal and vaginal wall blood¯ows. These observations may suggest the involvement of APO in the central mechanism of female sexual arousal function. APO may play a role in improving the hemodynamic mechanism of female sexual arousal function.
